Retrospective Evaluation of Transcatheter Edge-To-Edge Mitral Valve Repair in Dogs With Myxomatous Mitral Valve...

Transcatheter edge-to-edge repair (TEER) is an emerging minimally invasive mitral valve repair treatment for dogs with myxomatous mitral valve disease (MMVD), but reports on its outcomes are limited.

Describe the clinical characteristics and complications in dogs with MMVD undergoing TEER.

Twenty client-owned dogs with MMVD stages B2, C, and D.

Retrospective case series. Cases were identified by review of hospital medical records between September 2023 and September 2024.

Twenty dogs underwent TEER; of these, 13 (65%) survived. Seven dogs died within 9 days because of mitral leaflet tear or single-leaflet device attachment (4/7 dogs, 57.1%), tracheal collapse (1/7 dogs, 14.3%), presumed post-procedure neurologic deficit with a history of hydrocephalus (1/7 dogs, 14.3%), and presumed cardiogenic shock (1/7 dogs, 14.3%). Significant reductions in vertebral heart score (11.6 [9.6-13.1] vs. 11.0 [8.3-11.9] vertebrae; p < 0.01), vertebral left atrial size (2.90 [2.1-3.6] vs. 2.60 [2.0-3.3] vertebrae; p < 0.01), left atrium-to-aortic root ratio (2.09 [1.5-2.5] vs. 1.69 [1.3-2.2]; p < 0.05), left ventricular end-diastolic diameter normalized for body weight (2.1 [1.5-2.3] vs. 1.76 [1.4-2.2]; p < 0.05), regurgitant fraction (77.83 [73.2-83.0] vs. 55.38 [20.5-73.6] %; p < 0.05), and regurgitant volume (3.96 [2.1-6.2] vs. 1.25 [0.4-3.5] ml/kg; p < 0.05) were observed 3 months after TEER.

Transcatheter edge-to-edge repair resulted in a significant reduction in left atrium and ventricle size and should be further investigated as a potential treatment option for dogs with MMVD.